Last reviewed · How we verify

Vascace (CILAZAPRIL)

Phase 2 active Small molecule Under review Quality 0/100

Vascace (generic name: CILAZAPRIL) is a cilazapril drug. It is currently in Phase 2 development for Hypertensive disorder.

Cilazapril blocks the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor.

Vascace is a small molecule inhibitor of the angiotensin-converting enzyme. It works by inhibiting the angiotensin-converting enzyme, which is involved in blood pressure regulation.

Likelihood of approval
13.3% vs 15.3% industry baseline
If approved by FDA: likely 2031–2034
Steps remaining: Phase 3 → NDA/BLA submission
Confidence: Medium
Why this estimate
  • Baseline phase 2 → approval rate +15.3pp
    Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
  • Cardiovascular Phase 3 risk -2.0pp
    Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2031–2034 —
EMA EU 2032–2035 +0.7 yr
MHRA GB 2032–2035 +0.7 yr
Health Canada CA 2032–2036 +0.9 yr
TGA AU 2032–2036 +1.2 yr
PMDA JP 2032–2036 +1.5 yr
NMPA CN 2033–2037 +2.3 yr
MFDS KR 2032–2036 +1.4 yr
CDSCO IN 2032–2037 +1.8 yr
ANVISA BR 2033–2037 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameCILAZAPRIL
Drug classcilazapril
TargetAngiotensin-converting enzyme
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 2

Mechanism of action

Imagine your blood vessels are like roads in a city. Angiotensin II is like a traffic cop that makes the roads narrower, increasing blood pressure. Cilazapril removes this traffic cop, allowing the roads to stay open and blood pressure to decrease.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Vascace

What is Vascace?

Vascace (CILAZAPRIL) is a cilazapril drug, indicated for Hypertensive disorder.

How does Vascace work?

Cilazapril blocks the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor.

What is Vascace used for?

Vascace is indicated for Hypertensive disorder.

What is the generic name of Vascace?

CILAZAPRIL is the generic (nonproprietary) name of Vascace.

What drug class is Vascace in?

Vascace belongs to the cilazapril class. See all cilazapril drugs at /class/cilazapril.

What development phase is Vascace in?

Vascace is in Phase 2.

What are the side effects of Vascace?

Common side effects of Vascace include Amaurosis fugax, Urinary tract disorder, Ocular discomfort, Haemorrhagic stroke, Head discomfort, Tinnitus.

What does Vascace target?

Vascace targets Angiotensin-converting enzyme and is a cilazapril.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing